VistaGen Therapeutics Inc. [NASDAQ: VTGN] traded at a low on 11/17/22, posting a -1.49 loss after which it closed the day’ session at $0.15. The company report on November 17, 2022 that Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Preclinical data in “gold standard” MPTP non-human primate model of Parkinson’s disease show significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa.
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the publication of positive results from a preclinical study of the effects of AV-101, its oral NMDA receptor glycine site antagonist, in a widely used MPTP non-human primate model for reproducing motor complications of Parkinson’s disease (PD), including dyskinesia (sudden uncontrolled movements) observed in PD patients treated with levodopa (L-Dopa). Findings from the preclinical study were published in the international, peer-reviewed journal, Cells. In the preclinical study, AV-101 reduced L-Dopa-induced dyskinesias (LID) by about 25% while maintaining the antiparkinsonian response to L-Dopa.
The results of the trading session contributed to over 2179168 shares changing hands. Over the past one week, the price volatility of VistaGen Therapeutics Inc. stands at 17.34% while the volatility over the past one month is 12.76%.
The market cap for VTGN stock reached $24.19 million, with 206.81 million shares outstanding and 205.00 million shares in the current float. Compared to the average trading volume of 8.14M shares, VTGN reached a trading volume of 2179168 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about VistaGen Therapeutics Inc. [VTGN]?
William Blair have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 22, 2022. The new note on the price target was released on July 22, 2022, representing the official price target for VistaGen Therapeutics Inc. stock.
The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.02, with the Price to Sales ratio for VTGN stock in the period of the last 12 months amounting to 21.99. The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 0.21.
How has VTGN stock performed recently?
VistaGen Therapeutics Inc. [VTGN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.08. With this latest performance, VTGN shares gained by 29.63% in over the last four-week period, additionally sinking by -86.87% over the last 6 months – not to mention a drop of -93.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 53.51, with the RSI for the last a single of trading hit 56.00, and the three-weeks RSI is set at 48.68 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 0.1444, while it was recorded at 0.1535 for the last single week of trading, and 0.7593 for the last 200 days.
VistaGen Therapeutics Inc. [VTGN]: Deeper insight into the fundamentals
VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.
Insider trade positions for VistaGen Therapeutics Inc. [VTGN]
There are presently around $8 million, or 68.10% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: BLACKROCK INC. with ownership of 11,694,556, which is approximately -0.183% of the company’s market cap and around 0.30% of the total institutional ownership; FRANKLIN RESOURCES INC, holding 9,096,538 shares of the stock with an approximate value of $1.33 million in VTGN stocks shares; and STATE STREET CORP, currently with $0.82 million in VTGN stock with ownership of nearly 44.583% of the company’s market capitalization.
52 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 13,962,533 shares. Additionally, 63 investors decreased positions by around 96,247,393 shares, while 15 investors held positions by with 53,722,968 shares. The mentioned changes placed institutional holdings at 56,486,958 shares, according to the latest SEC report filing. VTGN stock had 18 new institutional investments in for a total of 1,199,158 shares, while 36 institutional investors sold positions of 87,278,481 shares during the same period.